Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)

• Status: Completed
• Trial end date: 2015-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this trial is to determine the efficacy of ofatumumab in patients with relapsed nodular lymphocyte predominant Hodgkin lymphoma (NLPHL).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Cologne
• Treatments: Antibodies, Monoclonal; Ofatumumab

Criteria

Inclusion Criteria:

• relapsed nodular lymphocyte predominant hodgkin lymphoma

• age 18 - 75

• review of diagnosis by experienced pathologist

• no major organ dysfunction

Exclusion Criteria:

• classical hodgkin lymphoma

• CD20 antibody treatment within the last 6 months prior enrollment

• chronic or current infectious disease requirering systemic antibiotics

• other past or current malignancy